Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
Standard
Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. / Berthold, Frank; Boos, Joachim; Burdach, Stefan; Erttmann, Rudolf; Henze, Günter; Hermann, Johann; Klingebiel, Thomas; Kremens, Bernhard; Schilling, Freimut H; Schrappe, Martin; Simon, Thorsten; Hero, Barbara.
in: LANCET ONCOL, Jahrgang 6, Nr. 9, 9, 2005, S. 649-658.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial.
AU - Berthold, Frank
AU - Boos, Joachim
AU - Burdach, Stefan
AU - Erttmann, Rudolf
AU - Henze, Günter
AU - Hermann, Johann
AU - Klingebiel, Thomas
AU - Kremens, Bernhard
AU - Schilling, Freimut H
AU - Schrappe, Martin
AU - Simon, Thorsten
AU - Hero, Barbara
PY - 2005
Y1 - 2005
N2 - BACKGROUND: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and
AB - BACKGROUND: Myeloablative megatherapy is commonly used to improve the poor outlook of children with high-risk neuroblastoma, yet its role is poorly defined. We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy. METHODS: 295 patients with high-risk neuroblastoma (ie, patients with stage 4 disease aged older than 1 year or those with MYCN-amplified tumours and stage 1, 2, 3, or 4S disease or stage 4 disease and
M3 - SCORING: Zeitschriftenaufsatz
VL - 6
SP - 649
EP - 658
JO - LANCET ONCOL
JF - LANCET ONCOL
SN - 1470-2045
IS - 9
M1 - 9
ER -